Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Top Links You Must Click On


Aequus BioPharma Appoints Ronald J. Berenson, M.D. President and CEO
Experienced industry entrepreneur to expand Aequus' product development opportunities

SEATTLE, Dec. 10, 2012 /PRNewswire/ -- Aequus BioPharma, a majority owned subsidiary of Cell Therapeutics, Inc., announced today that Ronald J. Berenson, M.D. was appointed President and CEO of Aequus. In his new position, Dr. Berenson will expand business and product development opportunities for Aequus' GlycoPolymer technology. Aequus is currently developing its GlycoPolymer technology aimed at creating novel biopharmaceuticals with improved pharmacokinetic properties that require less frequent injections than current therapies.

Dr. Berenson has more than 20 years of senior management experience in biotechnology, and was most recently an Entrepreneur in Residence at the University of Washington. He previously co-founded and served as President and CEO of HemaQuest Pharmaceuticals during the company's first three years, successfully ushering the company's programs into early clinical development of its lead compounds. His background also includes senior executive roles at numerous oncology-focused biotechnology companies, including Founder, Director, President and CEO of Xcyte Therapies, Inc. (which merged with Cyclacel), and Founder, Director, Executive Vice President, Chief Medical Officer and Chief Scientific Officer for CellPro, Inc. (CellPro). At CellPro, he was responsible for regulatory submissions that resulted in the U.S. Food and Drug Administration's (FDA) approval of CellPro's lead product, which was the first FDA-approved biological product in cell therapy. Since 2001, he has been on the Board of Ambassadors of the Fred Hutchinson Cancer Center. Dr. Berenson also has contributed to over 90 publications and holds 10 US patents. He completed his oncology training at Stanford University Medical Center, M.D. from Yale Medical School and obtained his B.S. from Stanford University.

"There are more than 100 therapeutic proteins on the market, and they represent one of the fastest growing classes of drugs today. Patient convenience and compliance continue to be issues with therapeutic proteins due to the need for frequent injections," said Dr. Berenson. "I believe that Aequus's novel approach could address these challenges with the potential to be applied to a wide spectrum of therapeutics."

In May 2012, Aequus reported proof of concept data on AQB-101, its novel hG-CSF-based therapeutic protein candidate that utilizes the GlycoPolymer technology approach. The AQB-101 glycoprotein possesses a plasma half-life that is comparable to PEGylated hG-CSF (Neulasta®), and significantly prolonged compared to the native form of hG-CSF (Neupogen®). 

About GlycoPolymer Technology

Aequus' modular GlycoPolymer technology represents a platform for efficiently creating "glycoengineered" protein-based biotherapeutics. Many protein biotherapeutics are on the market, but suffer from short half-lives, and thus require very frequent injections. By increasing the half-life of proteins, Aequus' technology offers the potential to create longer acting therapeutics, which can be administered much less frequently. This is expected to improve patient convenience and thus compliance leading to improved efficacy and clinical outcomes. The technology genetically ligates an external amino acid domain to a therapeutic protein or peptide candidate that results in additional N-linked glycosylation sites on the therapeutic. Additional N-linked glycan chains increase the plasma half-life and thus its duration of activity. The modular GlycoPolymer technology provides a more technically straightforward and predictable approach to extend the plasma half-life of a protein compared to the previous approaches designed to engineer novel glycosylation sites into proteins.

About Aequus BioPharma, Inc.

Headquartered on Bainbridge Island, WA, Aequus is a biopharmaceutical company committed to streamlining the development and manufacture of novel and "follow-on" therapeutic protein drugs.  Aequus is a majority owned subsidiary of Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC).

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of Aequus' modular GlycoPolymer technology (including, without limitation, the drug candidate AQB-101) include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with glycoengineered protein-based biotherapies (including, without limitation, AQB-101), in particular including, without limitation, that Aequus application of modular GlycoPolymer technology to biologically active proteins and peptides may not facilitate the development of therapeutic protein-based drugs that require less frequent dosing and offer improved patient convenience; that AQB-101 may not demonstrate the utility of the GlycoPolymer technology platform; determinations by regulatory, patent and administrative governmental authorities; CTI's and Aequus ability to continue to raise capital as needed to fund their operations; competitive factors; technological developments; costs of developing, producing and selling Aequus product candidates; and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, Aequus and CTI do not intend to update or alter such forward-looking statements whether as a result of new information, future events, or otherwise.

Contact:

Ronald Berenson, M.D.
206-790-1094
rberenson@aequusbio.com

SOURCE Aequus BioPharma, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Enterprise Open Source Magazine Latest Stories . . .

Unless you have been living under a rock the last year, you have probably heard about Docker. Docker describes itself as an open platform for distributed applications for developers and sysadmins. That sounds great, but why does it matter? Wait, virtualization isn’t new!? Virt...

DevOps is a discontinuous innovation in the way organizations develop and deliver software. And as with any new discontinuous innovation, the implication is that creative destruction will follow. Companies that hold on to legacy business and technology models, without pursuing the ev...
What are the benefits of using an enterprise-grade orchestration platform? In their session at 15th Cloud Expo, Jeff Tegethoff, CEO of Appcore, and Kedar Poduri, Senior Director of Product Management at Citrix Systems, will take a closer look at the architectural design factors neede...
StackIQ offers a comprehensive software suite that automates the deployment, provisioning, and management of Big Infrastructure. With StackIQ’s software, you can spin up fully configured big data clusters, quickly and consistently — from bare-metal up to the applications layer — and ma...
Here’s the presentation I gave at the Linux Foundation’s CloudOpen in Dusseldorf on October 13, 2014 titled Mixing Your Open Source Cloud Cocktail Add two parts virtualization, one part orchestration add a little networking shake and pour. Unfortunately cloud computing isn’...
There's fog coming to the world of IT. Some people are calling this "The Cloud." This fog turns everything inside out. It will take your monolithic applications, the guts of which are contained within large bodies of code, and break them apart so that discrete units of functionality a...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE